LLY.BA Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly launches Foundayo in UK, marking first European oral pill debut
Eli Lilly launched its oral weight-loss and type 2 diabetes pill, Foundayo, in the United Kingdom on Monday. The UK is the first European country to offer the...
Eli Lilly Weekly Insulin Wins NICE Recommendation, Cutting Annual Injections by 85%
The National Institute for Health and Care Excellence (NICE) recommended Eli Lilly’s once-weekly insulin, Onswik (efsitora alfa), for NHS use in treating type...
🟢 Eli Lilly is trading 4.51% up today as Foundayo prescriptions rose 14%
Eli Lilly is trading 4.51% up at ARS 36140.00 after weekly prescriptions for oral obesity pill Foundayo climbed 14% to approximately 38,900, while Novo...
🟢 Eli Lilly is trading 5.0% up
Eli Lilly is trading at ARS 36,320.00, up 5.0% from a comparison close of ARS 34,580.00 during regular trading. This is a price-action follow-up, so a separate...
🟢 Eli Lilly is trading 4.03% up today as investors rotate toward defensive healthcare stocks
Eli Lilly is trading 4.03% up at ARS 34560.00, outperforming a weaker broader market as investors rotate toward defensive healthcare stocks. - Healthcare has...
Eli Lilly faces CRA audit, over suspicious 2020 profit margins
The Canada Revenue Agency (CRA) launched an audit into Eli Lilly’s Canadian division. Federal court filings revealed the investigation on August 17, 2026. The...
Lilly's Oncology Bet Gets an FDA Fast Lane, but Can a Niche Cancer Drug Move the Needle for an $80 Billion Revenue Machine?
Shares of Eli Lilly surged 6.2% to $33,380 on August 7, rebounding sharply from a multi-day slide, after the FDA granted Breakthrough Therapy designation to...
Lilly's Oncology Bet Gets an FDA Fast Lane, but Can a Niche Cancer Drug Move the Needle for an $80 Billion Revenue Machine?
Shares of Eli Lilly surged 6.2% to $33,380 on August 7, rebounding sharply from a multi-day slide, after the FDA granted Breakthrough Therapy designation to...
Lilly's Oncology Bet Gets an FDA Fast Lane, but Can a Niche Cancer Drug Move the Needle for an $80 Billion Revenue Machine?
Shares of Eli Lilly surged 6.2% to $33,380 on August 7, rebounding sharply from a multi-day slide, after the FDA granted Breakthrough Therapy designation to...
🟢 Eli Lilly is trading 4.77% up today after Q2 earnings beat and raised 2026 revenue guidance
Eli Lilly is trading 4.77% up now at ARS 32940 after strong second-quarter results and higher full-year revenue guidance. • Q2 revenue reached $23.0 billion,...
🟢 Eli Lilly is trading 6.2% up today after Q2 earnings beat and FDA breakthrough designation
Eli Lilly is trading 6.2% up today at $33,380 following stronger-than-expected Q2 earnings, positive oncology news, and a broader market rally. • The company...
Lilly secures FDA breakthrough status for pancreatic cancer drug, olomorasib
Eli Lilly received FDA Breakthrough Therapy designation for its drug olomorasib. The treatment targets adult patients with KRAS G12C-mutant advanced...
Eli Lilly's Zepbound joins Indiana Medicaid, cutting state costs to $85
Eli Lilly’s GLP-1 weight-loss medications, Zepbound and Foundayo, are now accessible to eligible Indiana Medicaid beneficiaries. The state secured these drugs...
Eli Lilly invests $750M to expand US production, meeting record obesity demand
Eli Lilly and Company partnered with Resilience to invest $750 million in U.S. manufacturing capacity. This capital will expand domestic production for the...
🔴 Eli Lilly is trading 5.4% down today on healthcare sector margin concerns
Eli Lilly is trading 5.4% down at ARS 32,360.00 today, moving largely in step with a broader healthcare sector selloff. • The decline is primarily driven by...
🔴 Eli Lilly is trading 4.3% down today on healthcare sector margin concerns
Eli Lilly is trading 4.3% down at ARS 32,740.00 as managed care margin concerns weigh on the broader healthcare sector. • The move appears driven by...
Eli Lilly advances retatrutide, hitting 22.6% weight loss in Phase 3 trials
Eli Lilly and Company reported positive topline results from the TRIUMPH-2 and TRIUMPH-3 Phase 3 trials for retatrutide. The investigational drug is a...
Novo Nordisk sues Eli Lilly, alleging deceptive Zepbound and Mounjaro ads
Novo Nordisk filed a lawsuit Tuesday in U.S. federal court against Eli Lilly. The suit accuses Lilly of false advertising and unfair competition regarding its...
Eli Lilly buys AtaiBeckley for $2.8B, targeting psychedelic depression treatments
Eli Lilly has agreed to acquire clinical-stage biotech AtaiBeckley for an upfront cash payment of $2.8 billion. The deal prices AtaiBeckley at $6.75 per share....
Eli Lilly Target Raised to $1,385, Anticipating Earnings Beat
Bernstein SocGen Group increased its price target for Eli Lilly to $1,385 from $1,300. The firm maintains an Outperform rating on the pharmaceutical...